Anu Sharma, MD, FACP, FACR

Patients reported low overall satisfaction with New Zealand’s mandatory nationwide transition to an adalimumab biosimilar, though most said they are still taking it and appreciated its less-painful injections, according to a study.

Lower back pain remains the leading global cause of years lived with disability, while projections estimate that more than 800 million people will experience lower back pain by 2050, according to data published in The Lancet Rheumatology.